IBANDRONATE DURING 3 YEARS TREATMENT FOR OSTEOPOROSIS

伊班膦酸钠治疗骨质疏松症 3 年

• 批准号: 6117775
• 负责人: C. CONRAD JOHNSTON
• 金额: $ 1.7万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6117775
• 关键词: bone density; bone fracture; clinical research; diphosphonate; drug adverse effect; drug screening /evaluation; female; human subject; human therapy evaluation; intravenous administration; longitudinal animal study; osteoporosis; placebos; postmenopause; skeletal disorder chemotherapy; vertebrae; women's health

The purpose of this three year phase III study is to investigate the therapeutic effect of ibandronate in the long-term treatment of postmenopausal osteoporosis by evaluating the efficacy and safety of intermittent intravenous treatment using the incidence of new vertebral fractures as the primary endpoint. The specific objectives are: To determine whether Ibandronate prevents fractures and bone loss in women with established postmenopausal osteoporosis. To determine the type of side effects associated with the i.v. administration of Ibandronate. To determine the amount of Ibandronate in the blood following treatment and to estimate how long the drug stays in the blood.

这项为期三年的第三阶段研究的目的是调查 伊班膦酸钠长期治疗原发性高血压的疗效观察 绝经后骨质疏松症的疗效和安全性 利用新椎骨发生率进行间歇性静脉治疗 骨折作为主要终点。 具体目标是： 确定伊班膦酸盐是否能预防女性骨折和骨质流失 患有绝经后骨质疏松症 为了确定与i.v. 伊班膦酸盐的使用 测定治疗后血液中伊班膦酸盐的含量 并估计药物在血液中停留的时间